Ratings by Cantor Fitzgerald (Louis Chen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/29/2025 | Mesoblast Limited | MESO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2025 | Ardelyx, Inc | ARDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/9/2024 | Perspective Therapeutics Inc | CATX | New Coverage | Overweight (N/A) |
1.76 (4.97) |
182.39% | Details | |
| 8/31/2023 | Mesoblast Limited | MESO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/25/2023 | Ardelyx, Inc | ARDX | Upgrade | Overweight (Neutral) |
3.67 (6.19) |
68.66% | Details | |
| 5/4/2023 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/4/2023 | Theratechnologies Inc. | THTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2022 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/17/2022 | Ardelyx, Inc | ARDX | Upgrade | Neutral (Neutral) |
1.22 (6.19) |
407.38% | Details | |
| 11/17/2022 | Theratechnologies Inc. | THTX | New Coverage | Overweight (N/A) |
1.88 (3.39) |
80.32% | Details | |
| 11/17/2022 | Kempharm | KMPH | New Coverage | Overweight (N/A) |
4.39 (5.81) |
32.35% | Details | |
| 11/4/2022 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/23/2022 | Aerie Pharma | AERI | Downgrade | Neutral (Buy) |
10.99 (15.25) |
38.76% | Details | |
| 5/6/2022 | Ardelyx, Inc | ARDX | Downgrade | Neutral (Overweight) |
0.91 (1.22) |
34.07% | Details | |
| 3/1/2022 | Ardelyx, Inc | ARDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2022 | Vaxcyte | PCVX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/10/2021 | Vaxcyte | PCVX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2021 | Ardelyx, Inc | ARDX | New Coverage | Overweight (N/A) |
6.47 (6.19) |
-4.33% | Details | |
| 8/11/2020 | Mesoblast Limited | MESO | Maintain | Overweight (N/A) |
|
Details | ||
| 7/7/2020 | Vaxcyte | PCVX | New Coverage | Overweight (N/A) |
29.99 (59.29) |
97.7% | Details | |
| 5/26/2020 | Evofem Biosciences Inc | EVFM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2020 | Evofem Biosciences Inc | EVFM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2020 | Mesoblast Limited | MESO | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/7/2019 | Aerie Pharma | AERI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2019 | Mesoblast Limited | MESO | New Coverage | Overweight (N/A) |
5.74 (15.85) |
176.13% | Details | |
| 10/22/2019 | Aldeyra Therapeutics | ALDX | New Coverage | Overweight (N/A) |
5.84 (4.80) |
-17.81% | Details | |
| 10/22/2019 | Aerie Pharma | AERI | New Coverage | Overweight (N/A) |
19.59 (15.25) |
-22.15% | Details | |
| 10/16/2019 | Evofem Biosciences Inc | EVFM | New Coverage | Overweight (N/A) |
4.98 (0.01) |
-99.8% | Details | |
| 9/3/2019 | Correvio Pharma Corp. | CORV | New Coverage | Overweight (N/A) |
2.05 (0.42) |
-79.51% | Details |
